Georgia Karpathiou1, Celine Chauleur2, Sirine Hathroubi3, Cyril Habougit3, Michel Peoc'h3. 1. Department of Pathology, North Hospital, University Hospital of Saint-Etienne, 42055, Cedex 2, Saint-Étienne, France. gakarpath@yahoo.gr. 2. Department of Obstetrics and Gynecology, North Hospital, University Hospital of St-Etienne, Cedex 2, Saint-Étienne, France. 3. Department of Pathology, North Hospital, University Hospital of Saint-Etienne, 42055, Cedex 2, Saint-Étienne, France.
Abstract
BACKGROUND: Mammary and extra-mammary Paget disease is a rare form of intra-epithelial glandular neoplasm which is characteristically recurrent and necessitates multiple excisions that have an important impact on morbidity. Local immuno-modulating treatments have been applied with promising results, but the local immune markers of Paget disease have not been studied. AIM OF THE STUDY: To investigate the local immune micro-environment of Paget disease. MATERIALS AND METHODS: Sixty-four specimens from 41 patients, including cases with multiple recurrences and underlying primary neoplasm, have been studied for their expression of CD3, PD-L1 and CTLA-4. RESULTS: Nineteen cases were mammary; 22 were extra-mammary and involved the vulva, the anus, the inguinal region and the lower extremity. PD-L1 was not expressed by any neoplastic lesion or the associated lymphocytes. CTLA-4 expression was found in nine cases. Higher stromal CD3 expression and moderate levels of intra-epithelial CD3 expression were present in most cases. Biopsies, subsequent excision specimens and recurrences showed the same immunohistochemical profile of CD3 and PD-L1, although there were different levels of CTLA-4 in a few cases. The underlying lesions in mammary Paget disease showed the same immunohistochemical profile as the intra-epithelial neoplastic cells. The expression of the markers did not correlate with age, sex, localization or recurrence. CONCLUSION: Paget disease is characterized by an intense lymphocytic response, devoid of the immune-suppressive impact of the PD-L1 pathway, but with occasional CTLA-4 expression.
BACKGROUND: Mammary and extra-mammary Paget disease is a rare form of intra-epithelial glandular neoplasm which is characteristically recurrent and necessitates multiple excisions that have an important impact on morbidity. Local immuno-modulating treatments have been applied with promising results, but the local immune markers of Paget disease have not been studied. AIM OF THE STUDY: To investigate the local immune micro-environment of Paget disease. MATERIALS AND METHODS: Sixty-four specimens from 41 patients, including cases with multiple recurrences and underlying primary neoplasm, have been studied for their expression of CD3, PD-L1 and CTLA-4. RESULTS: Nineteen cases were mammary; 22 were extra-mammary and involved the vulva, the anus, the inguinal region and the lower extremity. PD-L1 was not expressed by any neoplastic lesion or the associated lymphocytes. CTLA-4 expression was found in nine cases. Higher stromal CD3 expression and moderate levels of intra-epithelial CD3 expression were present in most cases. Biopsies, subsequent excision specimens and recurrences showed the same immunohistochemical profile of CD3 and PD-L1, although there were different levels of CTLA-4 in a few cases. The underlying lesions in mammary Paget disease showed the same immunohistochemical profile as the intra-epithelial neoplastic cells. The expression of the markers did not correlate with age, sex, localization or recurrence. CONCLUSION: Paget disease is characterized by an intense lymphocytic response, devoid of the immune-suppressive impact of the PD-L1 pathway, but with occasional CTLA-4 expression.
Authors: Marina Stasenko; Gowtham Jayakumaran; Renee Cowan; Vance Broach; Dennis S Chi; Anthony Rossi; Travis J Hollman; Ahmet Zehir; Nadeem R Abu-Rustum; Mario M Leitao Journal: JCO Precis Oncol Date: 2020-09-15
Authors: Shakuntala H Mauzo; Michael T Tetzlaff; Denái R Milton; Alan E Siroy; Priyadharsini Nagarajan; Carlos A Torres-Cabala; Doina Ivan; Jonathan L Curry; Courtney W Hudgens; Jennifer A Wargo; Aysegul A Sahin; Curtis A Pettaway; Victor G Prieto; Phyu P Aung Journal: Cancers (Basel) Date: 2019-05-29 Impact factor: 6.639
Authors: Zoran Gatalica; Semir Vranic; Božo Krušlin; Kelsey Poorman; Phillip Stafford; Denisa Kacerovska; Wijendra Senarathne; Elena Florento; Elma Contreras; Alexandra Leary; April Choi; Gino K In Journal: Cancer Med Date: 2020-01-03 Impact factor: 4.452
Authors: Maryam Pourmaleki; Jonathan H Young; Nicholas D Socci; Sarah Chiang; Marcia Edelweiss; Yanyun Li; Mianlei Zhang; Lev Roshal; Dennis S Chi; Klaus J Busam; Ingo K Mellinghoff; Travis J Hollmann Journal: Oncotarget Date: 2019-10-22
Authors: Brendan John Guercio; Gopa Iyer; Wajih Zaheer Kidwai; Mario E Lacouture; Soleen Ghafoor; Anthony M Rossi; David N Assis; Ying-Bei Chen; Klaus J Busam; Yelena Y Janjigian; Komal Jhaveri; Darren R Feldman; Anne Capozzi; Vanessa Figueroa; Dean F Bajorin; Jonathan E Rosenberg; Travis J Hollmann; Samuel A Funt Journal: Case Rep Oncol Date: 2021-03-12